Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02436668 · ClinicalTrials.gov registry record · Phase 3
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
A Phase 3 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 3
- Development phase
- 430
- Enrollment target
NCT02436668 is a Phase 3 study that has completed, run by Pharmacyclics. The registered enrollment target is 430 participants.
The verdict
NCT02436668, a Phase 3 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 430 participants
- Enrollment target
Study Summary
This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2015-05 |
| Est. Completion | 2019-04-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02436668
The ClinicalTrials.gov registry entry for NCT02436668 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02436668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02436668 about?
NCT02436668 is a clinical study titled "Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)". This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
What is the current status of trial NCT02436668?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 430 participants. The study started on 2015-05. Estimated completion is 2019-04-25.
What interventions are being tested in trial NCT02436668?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02436668?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.